Sumi Shrishrimal Sells 2,830 Shares of iRhythm Technologies (NASDAQ:IRTC) Stock

iRhythm Technologies (NASDAQ:IRTC) EVP Sumi Shrishrimal sold 2,830 shares of the firm’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $128.44, for a total transaction of $363,485.20. Following the sale, the executive vice president owned 41,870 shares of the company’s stock, valued at approximately $5,377,782.80. The trade was a 6.33% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Sumi Shrishrimal also recently made the following trade(s):

• On Wednesday, February 25th, Sumi Shrishrimal sold 6,217 shares of iRhythm Technologies stock. The shares were sold at an average price of $135.42, for a total transaction of $841,906.14.

iRhythm Technologies Stock Up 1.7%

Shares of NASDAQ IRTC opened at $127.95 on Thursday. The company has a market capitalization of $4.14 billion, a P/E ratio of -91.39 and a beta of 1.09. The company has a debt-to-equity ratio of 4.25, a current ratio of 4.63 and a quick ratio of 4.48. The company has a 50 day simple moving average of $158.44 and a 200-day simple moving average of $169.85. iRhythm Technologies has a 1 year low of $92.52 and a 1 year high of $212.00.

iRhythm Technologies (NASDAQ:IRTC) last released its quarterly earnings data on Thursday, February 19th. The company reported $0.29 EPS for the quarter, beating analysts’ consensus estimates of $0.02 by $0.27. The firm had revenue of $208.89 million for the quarter, compared to analysts’ expectations of $202.61 million. iRhythm Technologies had a negative return on equity of 28.15% and a negative net margin of 5.96%.The firm’s quarterly revenue was up 27.1% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.04) earnings per share. On average, equities research analysts predict that iRhythm Technologies will post -1.98 earnings per share for the current year.

Trending Headlines about iRhythm Technologies

Here are the key news stories impacting iRhythm Technologies this week:

• Positive Sentiment: Management raised FY‑2026 revenue guidance to $870.0M–$880.0M versus consensus near $817M, signaling stronger demand and faster revenue growth than expected; the company also reported a solid February quarter beat (revenue +27% YoY and EPS above estimates), supporting the outlook.
• Neutral Sentiment: Analysts are recalibrating assumptions: several firms trimmed price targets while mostly keeping Buy/Overweight ratings — that creates mixed analyst signals as models are adjusted around the new guidance and profitability timing. Analyst coverage note
• Negative Sentiment: Clustered insider selling on March 2: multiple senior executives (CAO and several EVPs) sold shares — collectively roughly 17.8k shares for ≈$2.3M at ~ $128.44 per share — a mid‑single‑digit reduction in each holder’s stake. While insiders still retain material positions, the concentrated timing of the sales is likely weighing on near‑term sentiment. Insider trades alert

Analysts Set New Price Targets

Several analysts recently issued reports on the stock. Wells Fargo & Company decreased their target price on shares of iRhythm Technologies from $225.00 to $200.00 and set an “overweight” rating on the stock in a research report on Friday, February 20th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of iRhythm Technologies in a research report on Thursday, January 22nd. Morgan Stanley reissued an “overweight” rating on shares of iRhythm Technologies in a research report on Monday, January 12th. JPMorgan Chase & Co. decreased their price target on iRhythm Technologies from $240.00 to $215.00 and set an “overweight” rating on the stock in a research note on Friday, February 20th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $244.00 price objective on shares of iRhythm Technologies in a research note on Monday, January 12th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $211.62.

Hedge Funds Weigh In On iRhythm Technologies

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. MidFirst Bank acquired a new position in shares of iRhythm Technologies in the fourth quarter worth $235,000. Corient Private Wealth LLC grew its stake in iRhythm Technologies by 12.1% during the 4th quarter. Corient Private Wealth LLC now owns 1,764 shares of the company’s stock worth $313,000 after purchasing an additional 191 shares in the last quarter. Fuller & Thaler Asset Management Inc. grew its stake in iRhythm Technologies by 7.4% during the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 639,423 shares of the company’s stock worth $113,459,000 after purchasing an additional 44,175 shares in the last quarter. XTX Topco Ltd purchased a new stake in iRhythm Technologies during the 4th quarter worth about $855,000. Finally, RTW Investments LP acquired a new stake in iRhythm Technologies in the 4th quarter valued at about $209,732,000.

About iRhythm Technologies

iRhythm Technologies, Inc is a medical technology company that develops and commercializes wearable cardiac monitoring devices and associated data analytics services. Founded in 2006 and headquartered in San Francisco, California, the company’s flagship product is the Zio® patch, a discreet, single-use, continuous ECG recorder designed to monitor heart rhythms for up to 14 days. iRhythm’s digital diagnostics platform combines biosensor technology with proprietary algorithms to detect arrhythmias and streamline data interpretation for physicians.

The Zio service is prescribed by cardiologists and other healthcare providers to aid in the diagnosis of atrial fibrillation, bradycardia, tachycardia and other rhythm disorders.